MX2009009758A - Formulacion farmaceutica topica. - Google Patents

Formulacion farmaceutica topica.

Info

Publication number
MX2009009758A
MX2009009758A MX2009009758A MX2009009758A MX2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A MX 2009009758 A MX2009009758 A MX 2009009758A
Authority
MX
Mexico
Prior art keywords
glycol
pharmaceutical formulation
topical pharmaceutical
ether
polyhydric alcohol
Prior art date
Application number
MX2009009758A
Other languages
English (en)
Spanish (es)
Inventor
Adrian Francis Davis
Original Assignee
Futura Medical Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futura Medical Dev Ltd filed Critical Futura Medical Dev Ltd
Publication of MX2009009758A publication Critical patent/MX2009009758A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009009758A 2007-03-13 2008-02-15 Formulacion farmaceutica topica. MX2009009758A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0704846.5A GB0704846D0 (en) 2007-03-13 2007-03-13 Topical pharmaceutical formulation
PCT/GB2008/000540 WO2008110741A2 (en) 2007-03-13 2008-02-15 Topical pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2009009758A true MX2009009758A (es) 2009-09-24

Family

ID=37988913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009758A MX2009009758A (es) 2007-03-13 2008-02-15 Formulacion farmaceutica topica.

Country Status (21)

Country Link
US (1) US8541470B2 (enExample)
EP (2) EP2131813B1 (enExample)
JP (1) JP2010521442A (enExample)
CN (1) CN101663022A (enExample)
AU (1) AU2008224735B2 (enExample)
BR (1) BRPI0808887A2 (enExample)
CA (1) CA2680074C (enExample)
CO (1) CO6220926A2 (enExample)
DK (1) DK2131813T3 (enExample)
ES (1) ES2391914T3 (enExample)
GB (1) GB0704846D0 (enExample)
MX (1) MX2009009758A (enExample)
MY (1) MY149545A (enExample)
NZ (1) NZ579895A (enExample)
PL (1) PL2131813T3 (enExample)
PT (1) PT2131813E (enExample)
RU (1) RU2468794C2 (enExample)
SG (1) SG179480A1 (enExample)
TW (1) TWI367110B (enExample)
UA (1) UA100509C2 (enExample)
WO (1) WO2008110741A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545034C (en) * 2003-11-20 2013-03-05 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
BRPI0920448A2 (pt) 2008-10-17 2018-10-23 Xenon Pharmaceuticals Inc. compostos spiro-oxindol e seu uso como agentes terapêuticos
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2544852C2 (ru) 2009-10-14 2015-03-20 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CN105753877A (zh) 2012-04-12 2016-07-13 泽农医药公司 用作治疗剂的螺-羟吲哚化合物的不对称合成
MX379193B (es) * 2013-01-14 2025-03-11 Infirst Healthcare Ltd Composiciones en solucion solida y su uso en inflamacion cronica.
AU2014204739B2 (en) * 2013-01-14 2016-08-11 Infirst Healthcare Limited Compositions and methods for treating severe pain
SG11201505243PA (en) * 2013-02-04 2015-08-28 Infirst Healthcare Ltd Compositions and methods for treating chronic inflammation and inflammatory diseases
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
GB201502845D0 (en) * 2015-02-20 2015-04-08 Futura Medical Dev Ltd Topical pharmaceutical formulation
FR3041534B1 (fr) 2015-09-30 2019-03-15 Vetoquinol Sa Composition de nettoyant auriculaire
GB201609968D0 (en) * 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
EP3592336A1 (en) * 2017-03-07 2020-01-15 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Topical delivery systems for active compounds
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
GB2596286B (en) 2020-06-20 2023-01-25 Francis Davis Adrian Adherence to topical therapy
US20230270735A1 (en) 2020-07-27 2023-08-31 Incanthera (R&D) Ltd Topical formulation
GB2597526A (en) 2020-07-27 2022-02-02 Incanthera R&D Ltd Topical formulation
GB202012836D0 (en) 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
PE20011092A1 (es) 2000-02-14 2001-11-12 Procter & Gamble Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
AR041021A1 (es) 2002-08-22 2005-04-27 Novartis Consumer Health Sa Composicion topica
US7132452B2 (en) * 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
EP1588697A1 (en) 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
US20050244522A1 (en) 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents

Also Published As

Publication number Publication date
UA100509C2 (ru) 2013-01-10
CA2680074C (en) 2016-07-12
AU2008224735A1 (en) 2008-09-18
WO2008110741A3 (en) 2009-03-12
NZ579895A (en) 2012-02-24
US8541470B2 (en) 2013-09-24
PT2131813E (pt) 2012-10-31
CN101663022A (zh) 2010-03-03
WO2008110741A2 (en) 2008-09-18
SG179480A1 (en) 2012-04-27
AU2008224735B2 (en) 2013-04-18
CO6220926A2 (es) 2010-11-19
ES2391914T3 (es) 2012-12-03
PL2131813T3 (pl) 2012-11-30
EP2131813B1 (en) 2012-08-08
JP2010521442A (ja) 2010-06-24
DK2131813T3 (da) 2012-10-29
EP2452671A2 (en) 2012-05-16
RU2009136228A (ru) 2011-04-20
TWI367110B (en) 2012-07-01
GB0704846D0 (en) 2007-04-18
RU2468794C2 (ru) 2012-12-10
WO2008110741A8 (en) 2009-11-19
BRPI0808887A2 (pt) 2014-09-02
EP2131813A2 (en) 2009-12-16
CA2680074A1 (en) 2008-09-18
TW200836769A (en) 2008-09-16
US20100099767A1 (en) 2010-04-22
MY149545A (en) 2013-09-13

Similar Documents

Publication Publication Date Title
UA100509C2 (ru) Фармацевтическая композиция для местного применения нестероидного противовоспалительного препарата
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
BR112012029517A2 (pt) formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas.
PL1920759T3 (pl) Kompozycja kosmetyczna zawierająca fosforan alkilu i eter alkoholu tłuszczowego i glikol polietylenowy, sposoby i zastosowania
GB201009466D0 (en) System to generate and set up an adverstising campaign based on the insertion of advertising messages within an exchange of messages,
MX2012013700A (es) Composiciones aromatizantes y usos de las mismas.
CL2008003910A1 (es) Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida.
IL196169A0 (en) Bile acid derivatives and pharmaceutical compositions containing the same
WO2013060691A3 (en) Perfuming compositions and uses thereof
ZA200800818B (en) Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
WO2013064412A3 (en) Perfuming compositions and uses thereof
SI2058317T1 (sl) Derivat estra aminofosforjeve kisline in S1P receptorski modulator, ki ga vsebuje kot učinkovino
ZA200805714B (en) Antioxidant compositions useful in biodiesel and other fatty acid and acid ester compositions
EP2277861A4 (en) CYCLIC AMIN-1-CARBOXYLIC ACID EST DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH
NZ597326A (en) Matrix carrier compositions, methods and uses
FI20075547L (fi) Mainosten toimittaminen mobiilissa mainostamisjärjestelmässä
WO2008045189A3 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
IL201797A0 (en) Method for formulating odoriferous active ingredients in order to protect same and to increase the persistence thereof
PH12013500882A1 (en) Pharmaceutical compositions
MX2007006908A (es) Estabilizacion de esteres de glucocorticoides con acidos.
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
BRPI0815913A8 (pt) Composição de misturas antioxidantes apropriadas para uso em biodiesel.
GEP20125563B (en) 2-amino-2-phenylalkanol derivatives, preparation method thereof and pharmaceutical compositions containing same
GB201017113D0 (en) Surfactant vesicles
TH114523A (th) องค์ประกอบทำให้หอม และ การใช้ของสิ่งเหล่านั้น

Legal Events

Date Code Title Description
FG Grant or registration